Operations

Saneca Pharma appoints new CEO

February 19, 2018

Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Král. Richard, who has been the sales and marketing director at Saneca for almost three years, has previously worked for GlaxoSmithKline and Zentiva Group across the Central and Eastern Europe (CEE) and the Commonweath of Independent States (CIS) […]

Pharma Logi

February 19, 2018

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

February 16, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the closing of an underwritten public offering of 3,382,352 shares of its common stock, offered at a price of $34.00 per share to the […]

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

February 16, 2018

Heidelberg, Germany, February 15, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing of its previously announced public offering of 13,225,000 of its common shares at a public offering price of $2.00 per common share. The total includes 1,725,000 common […]

United Therapeutics Announces Settlement Of Patent Litigation With Actavis Laboratories FL, Inc. Relating To Orenitram

February 16, 2018

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2018 /PRNewswire/ — United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Actavis Laboratories FL, Inc. (“Actavis”) resolving ongoing litigation concerning certain patents relating to United Therapeutics’ product, Orenitram® (treprostinil) Extended-Release Tablets, and Actavis’ Abbreviated New Drug Application […]

Amicus Therapeutics Prices Underwritten Offering of Common Stock

February 16, 2018

CRANBURY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD) today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting underwriting discounts and commissions and estimated offering expenses payable […]

Proteomics International announces Strategic Alliance and Investment in CPR Pharma Services

February 15, 2018

PERTH, W. AUS.,  Feb 16, 2018 – MedTech pioneer Proteomics International (PILL; ASX: PIQ) has entered into a strategic alliance with CPR Pharma Services (CPR), targeting the high growth area of clinical trials and related research, with an offer to acquire 10% of CPR’s share capital through the issue of 4 million PIQ shares. This alliance […]

Buffett’s Firm Invests in Drugmaker Teva, Trims Phillips 66

February 15, 2018

OMAHA, NEB. Billionaire Warren Buffett’s company on Wednesday revealed a new investment in struggling Israeli drugmaker Teva Pharmaceuticals and trimmed its holdings in oil refiner Phillips 66 by selling 35 million shares back to the company for $3.3 billion.   Berkshire Hathaway Inc. disclosed those moves and several other tweaks to its stock holdings in […]

BMS, Nektar Ink Up-to-$3.6B Immuno-Oncology Combination Therapy

February 15, 2018

Bristol-Myers Squibb (BMS) will partner with Nektar Therapeutics on a combination cancer immunotherapy collaboration that could generate up to $3.6 billion-plus for Nektar—potentially the second-most-valuable immuno-onoclogy partnership ever launched.   The companies agreed to co-develop Nektar’s lead immuno-oncology program NKTR-214 in combination with BMS’ marketed cancer immunotherapy Opdivo® (nivolumab), as well as a combination of […]

Amicus Therapeutics Announces Public Offering of Common Stock

February 15, 2018

CRANBURY, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD) today announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint lead book-running managers, Cowen and Leerink Partners LLC are acting as co-book-running managers, and BofA […]

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

February 15, 2018

MADRID and BARCELONA, Spain, February 15, 2018 /PRNewswire/ —   Proceeds to support development of multiple novel first-in-class antibiotics   ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established […]

Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics Inc.

February 15, 2018

LAUSANNE, Switzerland, February 15, 2018 /PRNewswire/ —   ABAC develops new targeted antibiotics for patients with severe infections   Debiopharm Group ™ announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the […]

National Cancer Institute Awards Tosk $2 Million Cancer Drug Development Grant

February 15, 2018

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Tosk, Inc. announced today that it has received a two-year, $2 million Phase II SIBR grant from the National Cancer Institute (NCI) to support its kRAS oncogene drug research and development program, a high priority for the NCI.   Some 40 percent of all cancer patients carry an oncogenic kRAS gene that […]

Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

February 15, 2018

DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®precision immunotherapy technology platform, today announced the issuance of U.S. patent 9,879,053, covering the strain-independent amplification of human immunodeficiency virus, or HIV, nucleic acid sequences for use in […]

Education system failing to properly prepare STEM students for the working world

February 15, 2018

Survey of chemistry professionals finds 61% believe that curricula are not suitable for industry needs   The inability of chemistry to recruit new STEM students is a crisis for the industry according to more than a third (36%) of 180+ chemistry professionals from academia and industry, in a survey carried out by Elsevier’s Reaxys team. […]

Matthew Gagalis Joins Pri-Med Educational Development Team

February 14, 2018

BOSTON, Feb. 13, 2018 /PRNewswire/ — Matt Gagalis, a healthcare executive, was named General Manager, Continuing Medical Education Programs of DBC Pri-Med, LLC, a division of Diversified Communications, located in Boston, MA, that provides the latest medical education to primary care clinicians. Previously, Matt held leadership positions at RxAnte, an advanced healthcare analytics and clinical […]

ReForm Biologics Secures New Patent Expanding Coverage of Key Excipient Formulation for Antibody-Based Therapeutics

February 14, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 9,867,881 (the ‘881 patent). This patent, entitled “Viscosity-Reducing Excipient Compounds for Protein Formulations,” provides ReForm exclusive rights to certain formulations containing new concentrations of an excipient that significantly reduces […]

Sobi Names Linea Aspesi Vice President of Human Resources in North America

February 14, 2018

WALTHAM, Mass.–(BUSINESS WIRE)–Sobi, a pioneering international biopharmaceutical company dedicated to rare and difficult-to-treat diseases, announced today the appointment of Linea Aspesi as vice president of human resources for North America.   “Sobi is committed to growing our footprint in North America, and Linea’s experience both recruiting and developing teams will be critical to support this […]

Certara Launches Version 10 of D360, Its Industry-leading Drug Discovery Informatics Platform

February 14, 2018

D360 v10 delivers powerful and intuitive visualization and data presentation tools embedded into the informatics platform, enabling faster and deeper data understanding Certara®, the global leader in model-informed drug development and regulatory science, today announced the launch of version 10 of D360™, its data informatics platform for discovery scientists. D360 is a self-service data access, […]

Recipharm appoints President Development Services to drive end to end offering

February 14, 2018

Contract development and manufacturing organisation (CDMO) Recipharm has appointed Bernard Pluta to lead its new global development organisation. The newly established position forms part of the ongoing transformation of Recipharm’s Development Services, in which a total of 400 employees across six countries are united to deliver a comprehensive development offering. The scientific, chemical and pharmaceutical expertise will cover […]

Medidata Introduces New Edge Family of Products for Clinical Operations at SCOPE 2018

February 14, 2018

NEW YORK–(BUSINESS WIRE)–As clinical trials become more complex, sponsors and contract research organizations (CROs) are looking for a unified platform to help them overcome challenges such as dealing with disparate systems, complying with new regulatory requirements and managing an increasing variety and volume of data.   “Applying Machine Learning Frameworks to Improve Trial Outcomes” Tweet […]

Aptinyx Appoints Ashish Khanna Chief Financial Officer and Chief Business Officer

February 14, 2018

Evanston, Ill., Feb. 13, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Ashish Khanna, the company’s chief business officer, has also been appointed its chief financial officer. Mr. Khanna’s role includes oversight of all finance and accounting in addition to corporate and business development. He led […]

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

February 14, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the pricing of an underwritten public offering of 2,941,176 shares of its common stock, offered at a price of $34.00 per share to the […]

Ashfield U.S. hires two senior executives for new Medical Affairs business unit

February 14, 2018

Feb 13 2018-Fort Washington, PA: Ashfield U.S., part of UDG Healthcare plc, a global leader in commercialization services for the pharmaceutical and healthcare industry, is pleased to announce the appointment of Amy Van Sant as President of their new Medical Affairs business unit and Lee Ann Chaiken as Senior Vice President of Ashfield’s Pharmacovigilance business.   […]

FEEDBACK